ImmunoCellular Therapeutics, Ltd. announced the appointment of Steven J. Swanson, PhD, as Senior Vice President, Research. Dr. Swanson will lead the company's Stem-to-T-cell research program, which utilizes the patient's own hematopoietic stem cells to drive production of antigen-specific killer T-cells which then attack cancer cells. He will be responsible for all programmatic research and development, with the goal of identifying and advancing novel antigen-specific Stem-to-T-cell product candidates to the clinic.

Prior to joining the company, Dr. Swanson was an independent consultant advising biopharmaceutical companies on basic immunology research, bio-analytical procedures, immunogenicity assessment, regulatory affairs and product quality. Dr. Swanson spent 15 years at Amgen as Department Head for Clinical Immunology.